Metsera has reported encouraging early clinical data for its amylin analog, MET-233i, showing dose-dependent and sustained weight loss with potential for once-monthly dosing. These findings point to an emerging competitor in the obesity drug market alongside established weekly GLP-1 agonists. The biotech is advancing development plans for both monotherapy and combination regimens, aiming to address unmet needs in metabolic disease management.